|
Document and Entity Information
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
| Document Information [Line Items] | |
| Document Type | 6-K |
| Amendment Flag | false |
| Document Period End Date | Sep. 30, 2012 |
| Document Fiscal Year Focus | 2012 |
| Document Fiscal Period Focus | Q3 |
| Trading Symbol | ICLR |
| Entity Registrant Name | ICON PLC /ADR/ |
| Entity Central Index Key | 0001060955 |
| Current Fiscal Year End Date | --12-31 |
| X | ||||||||||
|
- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document. No definition available.
|
| X | ||||||||||
|
- Definition
End date of current fiscal year in the format --MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". No definition available.
|
| X | ||||||||||
|
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Trading symbol of an instrument as listed on an exchange. No definition available.
|
| X | ||||||||||
|
- Definition
Noncurrent capital government grants, which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
|
- Definition
Capital Redemption Reserve No definition available.
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, whichever is longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Balance Sheets (Parenthetical) (EUR €)
|
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Ordinary shares, par value | € 0.06 | € 0.06 |
| Ordinary shares, shares authorized | 100,000,000 | 100,000,000 |
| Ordinary shares, shares issued | 59,807,333 | 60,135,603 |
| Ordinary shares, shares outstanding | 59,807,333 | 60,135,603 |
| X | ||||||||||
|
- Definition
Face amount or stated value of common stock per share; generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Statements Of Operations (USD $)
In Thousands, except Share data, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Revenue: | ||||
| Gross revenue | $ 374,965 | $ 335,332 | $ 1,097,640 | $ 958,575 |
| Reimbursable expenses | (89,463) | (94,560) | (282,798) | (255,461) |
| Net revenue | 285,502 | 240,772 | 814,842 | 703,114 |
| Costs and expenses: | ||||
| Direct costs | 183,332 | 158,343 | 525,743 | 453,679 |
| Selling, general and administrative expense | 70,690 | 71,629 | 207,615 | 188,856 |
| Depreciation and amortization | 10,601 | 9,667 | 32,233 | 27,969 |
| Restructuring and other non-recurring items | 4,815 | 5,636 | 9,817 | |
| Total costs and expenses | 264,623 | 244,454 | 771,227 | 680,321 |
| Income from operations | 20,879 | (3,682) | 43,615 | 22,793 |
| Interest income | 243 | 378 | 936 | 905 |
| Interest expense | (495) | (247) | (1,454) | (602) |
| Income before provision for income taxes | 20,627 | (3,551) | 43,097 | 23,096 |
| Provision for income taxes | (2,889) | 888 | (8,424) | (4,329) |
| Net income/(loss) | $ 17,738 | $ (2,663) | $ 34,673 | $ 18,767 |
| Net income/(loss) per Ordinary Share: | ||||
| Basic | $ 0.30 | $ (0.04) | $ 0.58 | $ 0.31 |
| Diluted | $ 0.29 | $ (0.04) | $ 0.57 | $ 0.31 |
| Weighted average number of Ordinary Shares outstanding: | ||||
| Basic | 59,754,010 | 60,471,985 | 59,939,570 | 60,381,814 |
| Diluted | 60,366,137 | 61,063,020 | 60,391,199 | 61,096,464 |
| X | ||||||||||
|
- Definition
Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Cost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total costs of sales and operating expenses for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
Expenses charged against earnings in the period of an event that is infrequent in occurrence or unusual in nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Increase (Decrease) In Prepaid Expense And Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
Payments for Share Repurchase Costs No definition available.
|
| X | ||||||||||
|
- Definition
Proceeds From Government Grant No definition available.
|
| X | ||||||||||
|
- Definition
Amortization of Government Grants. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effect of exchange rate changes on cash balances held in foreign currencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of excess tax benefit (tax deficiency) that arises when compensation cost from non-qualified share-based compensation recognized on the entity's tax return exceeds (is less than) compensation cost from equity-based compensation recognized in financial statements. Excess tax benefit (tax deficiency) increases (decreases) net cash provided by financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to reacquire common stock during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow for cost incurred directly with the issuance of an equity security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to pay off an obligation from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tax impact on the adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
|
- Definition
Adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity, net of tax No definition available.
|
| X | ||||||||||
|
- Definition
Payments for Share Repurchase Costs No definition available.
|
| X | ||||||||||
|
- Definition
This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation". Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tax benefit associated with any equity-based compensation plan other than an employee stock ownership plan (ESOP). The tax benefit results from the deduction by the entity on its tax return for an award of stock that exceeds the cumulative compensation cost for common stock or preferred stock recognized for financial reporting. Includes any resulting tax benefit that exceeds the previously recognized deferred tax asset (excess tax benefits). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net of tax and reclassification adjustments of the change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity. Also includes the following: gain (loss) on foreign currency forward exchange contracts; foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; and gain (loss) on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain (loss) that has been designated and qualified as a hedging instrument for hedging of the foreign currency exposure of a net investment in a foreign operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of stock issued as a result of the exercise of stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Basis of Presentation
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
| Basis of Presentation |
1. Basis of Presentation
These
condensed consolidated financial statements, which have been
prepared in accordance with United States generally accepted
accounting principles (“US GAAP”), have not been
audited. The condensed consolidated financial statements reflect
all adjustments, which are, in the opinion of management, necessary
to present a fair statement of the operating results and financial
position for the periods presented. The preparation of the
condensed consolidated financial statements in conformity with US
GAAP requires management to make estimates and assumptions that
affect reported amounts and disclosures in the condensed
consolidated financial statements. Actual results could differ from
those estimates.
The
condensed consolidated financial statements should be read in
conjunction with the accounting policies and notes to the
consolidated financial statements included in ICON’s Form
20-F for the year ended December 31, 2011. Operating results for
the nine months ended September 30, 2012 are not necessarily
indicative of the results that may be expected for the fiscal
period ending December 31, 2012.
|
| X | ||||||||||
|
- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Goodwill
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
2. Goodwill
The
goodwill balance relates entirely to the clinical research
segment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for goodwill. No definition available.
|
|
Business Combinations
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations |
3. Business Combinations
Acquisition of PriceSpective
On
February 28, 2012 the Company acquired 100% of the common stock of
PriceSpective, a global leader in value strategy consulting, for an
initial cash consideration of $37.1
million. Headquartered in Philadelphia, and with offices
in London, Los Angeles, San Diego, Raleigh and Boston.
PriceSpective is a premier consultancy that has a strong reputation
for excellence in strategic pricing, market access, Health
Economics and Outcomes Research (“HEOR”), due diligence
support and payer engagement services. Since PriceSpective’s
inception in 2003, it has developed strategies for dozens of new
product launches, and hundreds of development and in-market
products, across 40+ disease areas. Further consideration of up to
$15.0 million may become payable if certain performance milestones
are achieved in respect of periods up to December 2012. On August
13, 2012 the Company paid $5.0 million in relation to performance
milestones for the year ended December 31, 2011. At September 30,
2012 the Company has recorded a liability of $10.0 million in
respect of the milestones for the year ended December 31,
2012.
The
following table summarizes the Company’s provisional
estimates of the fair values of assets acquired and the liabilities
assumed:
Acquisition of BeijingWits Medical
On
February 15, 2012 the Company acquired 100% of the common stock of
BeijingWits Medical, a leading Chinese CRO, for an initial cash
consideration of $9.0 million. BeijingWits Medical offers
full-service clinical development capabilities and has a strong
track record in clinical trial execution in China. It is a renowned
expert in Chinese regulatory processes and a leading advocate of
International Conference on Harmonisation Good Clinical Practice
(“ICH GCP”) in China. In addition to boosting the
Company’s service capabilities in the region, BeijingWits
Medical will also strengthen the Company’s presence through
the addition of over 100 highly qualified and experienced
professionals in Beijing, Shanghai, Chengdu, Guangzhou, Wuhan and
Hong Kong. Further consideration of up to $7.0 million may become
payable if certain performance milestones are achieved in respect
of periods up to December 31, 2013. At September 30,
2012 the Company has recorded a liability of $7.0 million in
respect of the additional consideration.
The
following table summarizes the Company’s provisional
estimates of the fair values of assets acquired and the liabilities
assumed:
*
Goodwill represents the acquisition of an established workforce
with experience in clinical trial execution and regulatory
processes in China.
Prior Period Acquisitions - Acquisition of Firecrest
Clinical
On
July 14, 2011 the Company acquired 100% of the common stock of
Firecrest Clinical Limited (“Firecrest”), a market
leading provider of technology solutions that boost investigator
site performance and study management, for an initial cash
consideration of €17.0 million ($24.5 million). Headquartered
in Limerick, Ireland, Firecrest Clinical provides a comprehensive
site performance management system that is used to improve
compliance consistency and execution of activities at investigative
sites. Further consideration of up to €33.0 million ($46.8
million) may become payable if certain performance milestones are
achieved in respect of periods up to June 30, 2013. At the date of
acquisition the Company recorded a liability of €31.3 million
($44.0 million) in relation to these performance milestones. In
March 2012 €3.0 million ($4.0million) was paid by the Company
in relation to performance milestones for the six months ended June
30, 2011 and in July 2012 a further €10 million ($12.5
million) was paid by the Company in relation to performance
milestones for the year ended December 31, 2011, both amounts
representing the full amount of additional consideration
potentially payable. At September 30, 2012 the Company has recorded
a liability of €19.3 million ($25.0 million) in relation to
the remaining performance milestones.
The
acquisition agreement also provided for certain working capital
targets to be achieved by Firecrest Clinical on
completion. In March 2012 the Company paid €0.4
million ($0.5 million) on completion of this
review.
The
acquisition of Firecrest Clinical has been accounted for as a
business combination in accordance with FASB ASC 805 Business Combinations.
The following table summarizes the estimated fair values of the
assets acquired and the liabilities assumed:
Prior Period Acquisitions - Acquisition of Oxford
Outcomes
On
January 14, 2011 the Company acquired approximately 80% of the
common stock of Oxford Outcomes Limited (“Oxford
Outcomes”), a leading international health outcomes
consultancy business, for an initial cash consideration of
£17.8 million ($27.6 million). Headquartered in
Oxford, United Kingdom, and with offices in the USA and Canada,
Oxford Outcomes provides specialist services in the areas of
patient reported outcomes (PRO), health economics, epidemiology and
translation and linguistic validation. On the same day a
put and call option was agreed between the Company and the selling
shareholders for the acquisition of the remaining common stock of
Oxford Outcomes during the year ended December 31, 2011 for cash
consideration of £3.8 million ($6.0 million). This
option was exercised in October 2011.
Additional
consideration of up to £8.0 million ($12.6 million) was
potentially payable if certain performance milestones were achieved
by Oxford Outcomes in respect of periods up to March 31, 2012;
£4.0 million ($6.3 million) in respect of the year ended March
31, 2011 and £4.0 million ($6.3 million) in respect of the
year ended March 31, 2012. Performance milestones in respect of
both periods have been achieved. £4.0 million ($6.3
million) was paid during the year ended December 31, 2011 in
respect of the milestone for the year ended March 31, 2011. A
liability of £4.0 million ($6.4 million) has been recorded by
the Company at September 30, 2012 in relation to the milestone for
the year ended March 31, 2012. A part payment of
£2.0 million ($3.3 million) in respect of this milestone was
made by the Company in October 2012.
The
acquisition agreement also provided for certain working capital
targets to be achieved by Oxford Outcomes on
completion. In May 2011 the Company paid an additional
£3.3 million ($5.1 million) in respect of certain elements of
this review and in March 2012 paid a further £0.8 million
($1.2 million) on completion of the review.
The
acquisition of Oxford Outcomes has been accounted for as a business
combination in accordance with FASB ASC 805 Business Combinations.
The following table summarizes the estimated fair values of the
assets acquired and the liabilities assumed:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Restructuring and other non-recurring items
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring and other non-recurring items |
4. Restructuring and other non-recurring items
Restructuring
and other non-recurring items recognized
comprise:
Restructuring Charges
Restructuring
charges of $4.5 million were recorded during the nine months ended
September 30, 2012 (inclusive of the release of $0.1 million
relating to the 2011 Restructuring Plans). During the nine months
ended September 30, 2012 the Company completed a review of its
operations to improve resource utilization throughout the business.
This review resulted in the adoption of a restructuring plan, to
include resource rationalizations in certain areas of the business
and a re-organization of available office space at the
Company’s Philadelphia facility. A restructuring charge of
$4.6 million was recognized during the nine months ended September
30, 2012; $3.4 million in respect of resource rationalizations and
$1.2 million in respect of lease termination and exit
costs.
Details
of the movement in this Restructuring Plan recognized during the
nine months ended September 30, 2012 are as
follows:
Prior Period Restructuring Charges
During
the three months ended March 31, 2011 the Company commenced a
review of its operations to improve resource utilization within the
business and better align resources to current and future growth
opportunities of the business. This review resulted in
the adoption of an initial restructuring plan (the “Q1 2011
Plan”), which resulted in the closure of the Company’s
facility in Edinburgh, United Kingdom and resource rationalizations
in certain of the more mature markets in which it
operates. A restructuring charge of $5.0 million was
recognized in respect of this plan during the three months ended
March 31, 2011, $1.0 million in respect of lease termination and
exit costs associated with the closure of the Edinburgh facility
and $4.0 million in respect of workforce reductions. $3.5 million
of costs recognized under the Q1 2011 Plan related to the clinical
research segment, while $1.5 million related to the central
laboratory business.
During
the three months ended September 30, 2011 the Company implemented a
further restructuring plan (the “Q3 2011 Plan”) which
resulted in the relocation of the Company’s facility in
Maryland, USA; and further resource rationalizations. A
restructuring charge of $4.8 million was recognized in respect of
this plan during the three months ended September 30, 2011, $0.9
million in respect of lease termination and exit costs associated
with the closure of the existing Maryland facility and $3.9 million
in respect of workforce reductions. All costs recognized
under the Q3 2011 Plan related to the clinical research
segment.
Details
of the movement in the 2011 Restructuring Plans recognized during
the year ended December 31, 2011 and for the nine months ended
September 30, 2012 are as follows:
Other Non-recurring Items
On
September 30, 2011 Mr. Peter Gray, retired as Chief Executive
Officer (“CEO”) of the Company, in accordance with the
provisions of his service agreement, which was terminable on twelve
months notice by either party. On October 1, 2011 Mr. Gray was
appointed Vice Chairman of the Board. On June 11, 2012 the Company
entered into an agreement with Mr. Gray whereby Mr. Gray’s
employment and directorship of ICON plc and other ICON group
companies would terminate on July 19, 2012. Under the
terms of this agreement Mr. Gray would be entitled to be paid
€160,000 ($200,000) in lieu of the balance of his notice
period and to receive a discretionary bonus of €194,000
($243,000) in respect of 2012. In addition, under the
agreement Mr. Gray’s unvested share options would vest on the
date of termination of his employment. The Company has
recognized a share-based compensation charge of $738,000 in respect
of these options during the nine months ended September 30, 2012,
$620,000 of which was recognized within restructuring and other
non-recurring items during the three months ended June 30,
2012.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Income Taxes
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes |
5. Income Taxes
Income
taxes recognized during the nine months ended September 30,
2012 comprise:
As
at September 30, 2012 the Company maintains a $5.5 million
liability (December 31, 2011: $7.7 million) for unrecognized tax
benefit, which is comprised of $4.6 million (December 31, 2011:
$6.5 million) related to items generating unrecognized tax benefits
and $0.9 million (December 31, 2011: $1.2 million) for interest and
related penalties to such items. The Company recognizes interest
accrued on unrecognized tax benefits as an additional income tax
expense.
The
Company has analyzed filing positions in all of the significant
federal, state and foreign jurisdictions where it is required to
file income tax returns, as well as open tax years in these
jurisdictions. The only periods subject to examination by the major
tax jurisdictions where the Company does business are 2007 through
2011 tax years. The Company does not believe that the outcome of
any examination will have a material impact on its financial
statements.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Net income per ordinary share
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income per ordinary share |
6. Net income per ordinary share
Basic
net income per ordinary share has been computed by dividing net
income available to ordinary shareholders by the weighted average
number of ordinary shares outstanding during the period. Diluted
net income per ordinary share is computed by adjusting the weighted
average number of ordinary shares outstanding during the period for
all potentially dilutive ordinary shares outstanding during the
period and adjusting net income for any changes in income or loss
that would result from the conversion of such potential ordinary
shares. There is no difference in net income used for basic and
diluted net income per ordinary share.
The
reconciliation of the number of shares used in the computation of
basic and diluted net income per ordinary share is as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share-based Awards
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Awards |
7. Share-based Awards
Share Options
On
July 21, 2008 the Company adopted the Employee Share Option Plan
2008 (the “2008 Employee Plan”) pursuant to which the
Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any employee, or any
director holding a salaried office or employment with the Company
or a Subsidiary for the purchase of ordinary shares. On the same
date, the Company also adopted the Consultants Share Option Plan
2008 (the “2008 Consultants Plan”), pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any consultant, adviser or
non-executive director retained by the Company or any Subsidiary
for the purchase of ordinary shares.
Each
option granted under the 2008 Employee Plan or the 2008 Consultants
Plan (together the “2008 Option Plans”) will be an
employee stock option, or NSO, as described in Section 422 or 423
of the Internal Revenue Code. Each grant of an option under the
2008 Options Plans will be evidenced by a Stock Option Agreement
between the optionee and the Company. The exercise price will be
specified in each Stock Option Agreement, however option prices
will not be less than 100% of the fair market value of an ordinary
share on the date the option is granted.
An
aggregate of 6.0 million ordinary shares have been reserved under
the 2008 Employee Plan, as reduced by any shares issued or to be
issued pursuant to options granted under the 2008 Consultants Plan,
under which a limit of 400,000 shares applies. Further,
the maximum number of ordinary shares with respect to which options
may be granted under the 2008 Employee Option Plan, during any
calendar year to any employee shall be 400,000 ordinary
shares. There is no individual limit under the 2008
Consultants Plan. No options may be granted under
the 2008 Option Plans after July 21, 2018.
On
January 17, 2003 the Company adopted the Share Option Plan 2003
(the “2003 Share Option Plan”) pursuant to which the
Compensation and Organization Committee of the Board may grant
options to officers and other employees of the Company or its
subsidiaries for the purchase of ordinary shares. Each
grant of an option under the 2003 Share Option Plan will be
evidenced by a Stock Option Agreement between the employee and the
Company. The exercise price will be specified in each Stock Option
Agreement.
An
aggregate of 6.0 million ordinary shares have been reserved under
the 2003 Share Option Plan; and, in no event will the number of
ordinary shares that may be issued pursuant to options awarded
under the 2003 Share Option Plan exceed 10% of the outstanding
shares, as defined in the 2003 Share Option Plan, at the time of
the grant, unless the Board expressly determines otherwise.
Further, the maximum number of ordinary shares with respect to
which options may be granted under the 2003 Share Option Plan
during any calendar year to any employee shall be 400,000 ordinary
shares. No options can be granted after January 17,
2013.
Share
option awards are granted with an exercise price equal to the
market price of the Company’s shares at date of
grant. Share options typically vest over a period of
five years from date of grant and expire eight years from date of
grant. The maximum contractual term of options
outstanding at September 30, 2012 is eight years.
The
following table summarizes option activity for the nine months
ended September 30, 2012:
The
Company has granted options with fair values ranging from $3.68 to
$13.93 per option or a weighted average fair value of $8.03 per
option. The Company issues ordinary shares for all
options exercised. The total amount of fully vested share options
which remained outstanding at September 30, 2012, was
2,708,837. Fully vested share options at September 30,
2012 have an average remaining contractual term of 3.4 years, an
average exercise price of $22.41 and a total intrinsic value of
$11.7 million. The total intrinsic value of options exercised
during the nine months ended September 30, 2012, was $4.8 million
(September 30, 2011: $1.5 million).
The
following table summarizes the movement in non-vested share options
for the nine months ended September 30, 2012:
Fair value of Stock Options Assumptions
The
weighted average fair value of options granted during the period
ended September 30, 2012 and September 30, 2011 was calculated
using the Black-Scholes option pricing model. The
weighted average fair values and assumptions used were as
follows:
Expected
volatility is based on the historical volatility of our common
stock over a period equal to the expected term of the options; the
expected life represents the weighted average period of time that
options granted are expected to be outstanding given consideration
to vesting schedules, and our historical experience of past vesting
and termination patterns. The risk-free rate is based on the U.S.
government zero-coupon bonds yield curve in effect at time of the
grant for periods corresponding with the expected life of the
option.
Restricted Share Units
On
July 21, 2008 the Company adopted the 2008 Employees Restricted
Share Unit Plan (the “2008 RSU Plan”) pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may select any employee, or any director holding
a salaried office or employment with the Company, or a Subsidiary
to receive an award under the plan. An aggregate of 1.0
million ordinary shares have been reserved for issuance under the
2008 RSU Plan. Restricted Share Units (“RSU’s”)
typically vest over periods ranging from one to three years. The
Company issues new ordinary shares on the date of vesting of the
RSU.
The
Company has awarded RSU’s to certain key executives of the
Group. The following table summarizes RSU activity for the nine
months ended September 30, 2012:
The
fair value of RSU’s vested for the nine months ended
September 30, 2012 totaled $0.0 million (2011: $0.1
million).
Non-cash stock compensation expense
Non-cash
stock compensation expense for the nine months ended September 30,
2012 has been allocated as follows:
Total
non-cash stock compensation expense not yet recognized at September
30, 2012 amounted to $21.2 million. The weighted average
period over which this is expected to be recognized is 3.0
years. Total tax benefit recognized in additional paid
in capital related to the non-cash compensation expense amounted to
$0.9 million for the nine months ended September 30, 2012
(September 30, 2011: $0.5 million).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangements by Share-based Payment Award [Text Block] No definition available.
|
|
Share Capital
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
| Share Capital |
8. Share Capital
Share Repurchase Program
On
October 27, 2011 the Company announced its intention to commence a
share repurchase program of up to $50 million. On November 22, 2011
the Company entered into two separate share repurchase plans of $10
million each, covering the periods November 23, 2011 to December
31, 2011 and January 1, 2012 to February 20, 2012
respectively. On February 21, 2012 the Company entered
into a further share repurchase plan of $20 million, covering the
period February 22, 2012 to April 22, 2012. On April 27,
2012 the Company entered into a fourth share repurchase plan of up
to $20 million, covering the period April 27, 2012 to July 18,
2012. On July
30, 2012 the Company entered into a fifth share repurchase plan of
up to $10 million, covering the period July 30, 2012 to October 26,
2012. The
Company intends to enter further share repurchase plans to effect
the share repurchase program in accordance with Rule 10b-18 and
Rule 10b5-1 of the Securities Exchange Act of 1934, the
authorization granted at the Company’s annual general
meeting, applicable laws and regulations and the Listing Rules of
the Irish Stock Exchange.
Under
the repurchase program, a broker will purchase the Company’s
American Depositary Shares (“ADSs”) from time to time
on the open market or in privately negotiated transactions in
accordance with agreed terms and limitations. ADSs
purchased will be deposited with the Depositary under the
Company’s ADR facility against delivery of the underlying
Ordinary Shares, which will be repurchased by the Company on the
Irish Stock Exchange in compliance with the Company’s share
repurchase authorization and applicable laws and regulations.
Separately, Ordinary Shares traded on the Irish Stock Exchange may
also be repurchased on behalf of the Company. The
program is designed to allow share repurchases during periods when
the Company would ordinarily not be permitted to do so because it
may be in possession of material non-public or price-sensitive
information, applicable insider trading laws or self-imposed
trading blackout periods. The Company’s
instructions to the broker are irrevocable and the trading
decisions in respect of the repurchase program will be made
independently of and uninfluenced by the Company. The
Company confirms that on entering the repurchase plans it had no
material non-public, price-sensitive or inside information
regarding the Company or its securities. Furthermore, the Company
will not enter into additional plans whilst in possession of such
information.
The
timing and actual number of shares repurchased will be dependent on
market conditions, legal and regulatory requirements and the other
terms and limitations contained in the plans. In
addition, share repurchases may be suspended or discontinued in
certain circumstances in accordance with the agreed
terms. Therefore, there can be no assurance as to the
timing or number of shares that may be repurchased under the
repurchase program. All
Ordinary Shares repurchased by the Company will be
cancelled.
During
the nine months ended September 30, 2012 738,341 ordinary shares
were repurchased by the Company for a total consideration of $15.6
million. As at September 30, 2012 1,283,938 ordinary
shares have been repurchased by the Company for a total
consideration of $24.6 million. All ordinary shares repurchased by
the Company were cancelled and the nominal value of these shares
transferred to a capital redemption reserve fund as required under
Irish Company Law.
|
| X | ||||||||||
|
- Definition
Share Repurchase Program Disclosure No definition available.
|
|
Business Segment Information
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Segment Information |
9. Business Segment Information
The
Company is a contract research organization (“CRO”),
providing outsourced development services on a global basis to the
pharmaceutical, biotechnology and medical device industries. It
specializes in the strategic development, management and analysis
of programs that support all stages of the clinical development
process - from compound selection to Phase I-IV clinical
studies. The Company has the expertise and capability to
conduct clinical trials in most major therapeutic areas on a global
basis and has the operational flexibility to provide development
services on a stand-alone basis or as part of an integrated
“full service” solution. The Company has
expanded predominately through internal growth, together with a
number of strategic acquisitions to enhance its expertise and
capabilities in certain areas of the clinical development
process. The Company also provides laboratory services
through its central laboratory business, which includes the
Company’s central laboratories located in Dublin, New York,
India, Singapore and China.
The
Company determines and presents operating segments in accordance
with FASB ASC 280-10 Disclosures about Segments of
an Enterprise and Related Information, based on the
information that is internally provided to the Chief Executive
Officer and Chief Financial Officer, who together are considered
the Company’s chief operating decision maker. The Company has
determined that it has two reportable segments, its Clinical
Research segment and Central Laboratory
segment.
The
Company's areas of operation outside of Ireland include the United
States, United Kingdom, France, Germany, Italy, Spain, The
Netherlands, Sweden, Finland, Denmark, Belgium, Switzerland,
Poland, Czech Republic, Lithuania, Latvia, Russia, Ukraine,
Hungary, Israel, Romania, Canada, Mexico, Brazil, Colombia,
Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand,
Taiwan, Singapore, The Philippines, Australia, New Zealand, and
South Africa.
Segment
information as at September 30, 2012 and December 31, 2011 and for
the three and nine months ended September 30, 2012 and September
30, 2011 is as follows:
a)
The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
b) The
distribution of net revenue by business segment was as
follows:
c) The
distribution of income from operations by geographical area was as
follows:
d) The
distribution of income from operations by business segment was as
follows:
e)
The distribution of property, plant and equipment, net, by
geographical area was as follows:
f)
The distribution of property, plant and equipment, net, by business
segment was as follows:
g)
The distribution of depreciation and amortization by geographical
area was as follows:
h)
The distribution of depreciation and amortization by business
segment was as follows:
i)
The distribution of total assets by geographical area was as
follows:
j)
The distribution of total assets by business segment was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Goodwill (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Business Combinations (Tables)
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PriceSpective LLC
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The
following table summarizes the Company’s provisional
estimates of the fair values of assets acquired and the liabilities
assumed:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BeijingWits Medical Limited
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The
following table summarizes the Company’s provisional
estimates of the fair values of assets acquired and the liabilities
assumed:
*
Goodwill represents the acquisition of an established workforce
with experience in clinical trial execution and regulatory
processes in China.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Firecrest Clinical Limited
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The
following table summarizes the estimated fair values of the assets
acquired and the liabilities assumed:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Oxford Outcomes Limited
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The
following table summarizes the estimated fair values of the assets
acquired and the liabilities assumed:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Preliminary Fair Values of Assets Acquired and Liabilities Assumed Related to Acquisition No definition available.
|
|
Restructuring and other non-recurring items (Tables)
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring and Other non-recurring | Restructuring
and other non-recurring items recognized
comprise:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Details of Movement in Restructuring Provisions Recognized | Details
of the movement in this Restructuring Plan recognized during the
nine months ended September 30, 2012 are as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prior Period Restructuring Charges | Details
of the movement in the 2011 Restructuring Plans recognized during
the year ended December 31, 2011 and for the nine months ended
September 30, 2012 are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Restructuring Charges [Table Text Block] No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of restructuring and related costs by type of restructuring including the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Income Taxes (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Tax Expense (Benefit) |
Income
taxes recognized during the nine months ended September 30,
2012 comprise:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Net income per ordinary share (Tables)
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share | The
reconciliation of the number of shares used in the computation of
basic and diluted net income per ordinary share is as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations. No definition available.
|
|
Share-based Awards (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Stock Option Activity | The
following table summarizes option activity for the nine months
ended September 30, 2012:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Movement in Non-Vested Share Options | The
following table summarizes the movement in non-vested share options
for the nine months ended September 30, 2012:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Weighted Average Fair Values and Assumptions Used | The
weighted average fair value of options granted during the period
ended September 30, 2012 and September 30, 2011 was calculated
using the Black-Scholes option pricing model. The
weighted average fair values and assumptions used were as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of RSU Activity | The
following table summarizes RSU activity for the nine months ended
September 30, 2012:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-cash Stock Compensation Expense | Non-cash
stock compensation expense for the nine months ended September 30,
2012 has been allocated as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Schedule of Non Cash Stock Compensation Expense No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the changes in outstanding nonvested shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Business Segment Information (Tables)
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Net Revenue by Geographical Area | a)
The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Net Revenue by Business Segment | b) The
distribution of net revenue by business segment was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Income from Operations by Geographical Area |
c) The
distribution of income from operations by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Income from Operations by Business Segment | d) The
distribution of income from operations by business segment was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Property, Plant and Equipment, Net, by Geographical Area | e)
The distribution of property, plant and equipment, net, by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Property, Plant and Equipment, Net, by Business Segment | f)
The distribution of property, plant and equipment, net, by business
segment was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Depreciation and Amortization by Geographical Area | g)
The distribution of depreciation and amortization by geographical
area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Depreciation and Amortization by Business Segment | h)
The distribution of depreciation and amortization by business
segment was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Total Assets by Geographical Area | i)
The distribution of total assets by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Total Assets by Business Segment | j)
The distribution of total assets by business segment was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Net Revenue by Business Segment No definition available.
|
| X | ||||||||||
|
- Definition
Operating Income by Geography No definition available.
|
| X | ||||||||||
|
- Definition
Operating Income by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Property, Plant and Equipment by Geography No definition available.
|
| X | ||||||||||
|
- Definition
Revenues by Geography No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Depreciation And Amortization Expense By Geographical Area No definition available.
|
| X | ||||||||||
|
- Definition
Schedule of Depreciation and Amortization Expense by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Schedule of Property, Plant and Equipment, Net by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Total Assets By Geographic Area No definition available.
|
| X | ||||||||||
|
- Definition
Schedule of Total Assets by Segment No definition available.
|
|
Goodwill (Detail) (USD $)
In Thousands, unless otherwise specified |
9 Months Ended | 12 Months Ended |
|---|---|---|
|
Sep. 30, 2012
|
Dec. 31, 2011
|
|
| Goodwill [Line Items] | ||
| Opening balance | $ 253,393 | $ 175,860 |
| Current period acquisitions | 68,521 | 83,656 |
| Prior period acquisitions | 534 | |
| Foreign exchange movement | 2,816 | (6,123) |
| Closing balance | $ 325,264 | $ 253,393 |
| X | ||||||||||
|
- Definition
Goodwill Acquired Prior Period No definition available.
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of goodwill acquired in the period and allocated to the reportable segment. The value is stated at fair value based on the purchase price allocation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The increase (decrease) to the recorded value of goodwill for foreign currency translation adjustments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Business Combinations - Additional Information (Detail)
|
1 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aug. 13, 2012
PriceSpective LLC
USD ($)
|
Sep. 30, 2012
PriceSpective LLC
USD ($)
|
Feb. 28, 2012
PriceSpective LLC
USD ($)
|
Feb. 28, 2012
PriceSpective LLC
Maximum
USD ($)
|
Sep. 30, 2012
BeijingWits Medical Limited
USD ($)
|
Feb. 15, 2012
BeijingWits Medical Limited
USD ($)
|
Feb. 15, 2012
BeijingWits Medical Limited
Maximum
USD ($)
|
Feb. 15, 2012
BeijingWits Medical Limited
Minimum
Employee
|
Jul. 31, 2012
Firecrest Clinical Limited
USD ($)
|
Jul. 31, 2012
Firecrest Clinical Limited
EUR (€)
|
Sep. 30, 2012
Firecrest Clinical Limited
USD ($)
|
Sep. 30, 2012
Firecrest Clinical Limited
EUR (€)
|
Mar. 31, 2012
Firecrest Clinical Limited
USD ($)
|
Mar. 31, 2012
Firecrest Clinical Limited
EUR (€)
|
Jul. 14, 2011
Firecrest Clinical Limited
USD ($)
|
Jul. 14, 2011
Firecrest Clinical Limited
EUR (€)
|
Jul. 14, 2011
Firecrest Clinical Limited
Maximum
USD ($)
|
Jul. 14, 2011
Firecrest Clinical Limited
Maximum
EUR (€)
|
Dec. 31, 2011
Oxford Outcomes Limited
USD ($)
|
Dec. 31, 2011
Oxford Outcomes Limited
GBP (£)
|
Sep. 30, 2012
Oxford Outcomes Limited
USD ($)
|
Sep. 30, 2012
Oxford Outcomes Limited
GBP (£)
|
Mar. 31, 2012
Oxford Outcomes Limited
USD ($)
|
Mar. 31, 2012
Oxford Outcomes Limited
GBP (£)
|
May 31, 2011
Oxford Outcomes Limited
USD ($)
|
May 31, 2011
Oxford Outcomes Limited
GBP (£)
|
Jan. 14, 2011
Oxford Outcomes Limited
USD ($)
|
Jan. 14, 2011
Oxford Outcomes Limited
GBP (£)
|
Sep. 30, 2012
Oxford Outcomes Limited
Maximum
USD ($)
|
Sep. 30, 2012
Oxford Outcomes Limited
Maximum
GBP (£)
|
Mar. 31, 2012
Oxford Outcomes Limited
Maximum
USD ($)
|
Mar. 31, 2012
Oxford Outcomes Limited
Maximum
GBP (£)
|
Mar. 31, 2011
Oxford Outcomes Limited
Maximum
USD ($)
|
Mar. 31, 2011
Oxford Outcomes Limited
Maximum
GBP (£)
|
Dec. 31, 2011
Oxford Outcomes Limited
Put and call option
USD ($)
|
Dec. 31, 2011
Oxford Outcomes Limited
Put and call option
GBP (£)
|
Oct. 01, 2012
Subsequent Event
Oxford Outcomes Limited
USD ($)
|
Oct. 01, 2012
Subsequent Event
Oxford Outcomes Limited
GBP (£)
|
|
| Business Acquisition [Line Items] | ||||||||||||||||||||||||||||||||||||||
| Percentage of common stock acquired | 100.00% | 100.00% | 100.00% | 100.00% | 80.00% | 80.00% | ||||||||||||||||||||||||||||||||
| Cash consideration | $ 37,132,000 | $ 9,000,000 | $ 24,463,000 | € 17,000,000 | $ 27,585,000 | £ 17,800,000 | $ 6,000,000 | £ 3,800,000 | ||||||||||||||||||||||||||||||
| Additional consideration | 15,000,000 | 7,000,000 | 46,800,000 | 33,000,000 | 12,600,000 | 8,000,000 | 6,300,000 | 4,000,000 | 6,300,000 | 4,000,000 | ||||||||||||||||||||||||||||
| Further consideration paid in relation to certain performance milestones achieved | 5,000,000 | 12,500,000 | 10,000,000 | 6,300,000 | 4,000,000 | 3,300,000 | 2,000,000 | |||||||||||||||||||||||||||||||
| Additional consideration liability | 10,000,000 | 7,000,000 | 25,000,000 | 19,300,000 | 44,000,000 | 31,300,000 | 6,400,000 | 4,000,000 | ||||||||||||||||||||||||||||||
| Addition of new employees | 100 | |||||||||||||||||||||||||||||||||||||
| First element of additional consideration paid | 4,000,000 | 3,000,000 | ||||||||||||||||||||||||||||||||||||
| Additional amount Company paid on completion of working capital review | $ 500,000 | € 400,000 | $ 1,200,000 | £ 800,000 | $ 5,100,000 | £ 3,300,000 | ||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Business Acquisition, Accrued Consideration Payable No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Additional Cash Paid No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Cost of Acquired Entity, Additional Cash Paid No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Cost of Acquired Entity, Consideration Paid No definition available.
|
| X | ||||||||||
|
- Definition
Number of Employees No definition available.
|
| X | ||||||||||
|
- Definition
Amount of potential cash payments that could result from the contingent consideration arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Percentage of voting equity interests acquired in the business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PriceSpective LLC (Detail) (PriceSpective LLC, USD $)
In Thousands, unless otherwise specified |
Feb. 28, 2012
|
|||
|---|---|---|---|---|
|
PriceSpective LLC
|
||||
| Business Acquisition [Line Items] | ||||
| Property, plant and equipment | $ 256 | |||
| Goodwill | 53,382 | [1] | ||
| Cash and cash equivalents | 2,311 | |||
| Accounts receivable | 2,662 | |||
| Unbilled revenue | 1,140 | |||
| Other current assets | 236 | |||
| Current liabilities | (7,855) | |||
| Liability arising from contingent consideration arrangement | (15,000) | |||
| Net assets acquired | 37,132 | |||
| Cash consideration | 37,132 | |||
| Contingent consideration | 15,000 | |||
| Amount of total consideration | 52,132 | |||
| Liabilities included in preliminary purchase price allocation | (15,000) | |||
| Net assets acquired | $ 37,132 | |||
|
||||
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Accounts Receivable and Other Assets No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Deferred Revenue No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Noncurrent portion of the fair value as of the acquisition date of potential payments under the contingent consideration arrangement, including cash and shares as applicable. No definition available.
|
| X | ||||||||||
|
- Definition
The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash and cash equivalents acquired in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to current liabilities of the acquired entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Beijing Wits Medical Limited (Detail) (BeijingWits Medical Limited, USD $)
In Thousands, unless otherwise specified |
Feb. 15, 2012
|
|||
|---|---|---|---|---|
|
BeijingWits Medical Limited
|
||||
| Business Acquisition [Line Items] | ||||
| Property, plant and equipment | $ 172 | |||
| Goodwill | 15,139 | [1] | ||
| Cash and cash equivalents | 587 | |||
| Accounts receivable | 657 | |||
| Unbilled revenue | 176 | |||
| Other current assets | 228 | |||
| Non current assets | 48 | |||
| Current liabilities | (1,007) | |||
| Liability arising from contingent consideration arrangement | (7,000) | |||
| Net assets acquired | 9,000 | |||
| Cash consideration | 9,000 | |||
| Contingent consideration | 7,000 | |||
| Amount of total consideration | 16,000 | |||
| Liabilities included in preliminary purchase price allocation | (7,000) | |||
| Net assets acquired | $ 9,000 | |||
|
||||
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Accounts Receivable and Other Assets No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Deferred Revenue No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Noncurrent portion of the fair value as of the acquisition date of potential payments under the contingent consideration arrangement, including cash and shares as applicable. No definition available.
|
| X | ||||||||||
|
- Definition
The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash and cash equivalents acquired in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to current liabilities of the acquired entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to noncurrent assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Firecrest (Detail) (Firecrest Clinical Limited)
In Thousands, unless otherwise specified |
Jul. 14, 2011
USD ($)
|
Jul. 14, 2011
EUR (€)
|
Jul. 14, 2011
Technology Assets
USD ($)
|
Jul. 14, 2011
Customer relationships acquired
USD ($)
|
Jul. 14, 2011
Order Backlog
USD ($)
|
Jul. 14, 2011
Trade Names
USD ($)
|
|||
|---|---|---|---|---|---|---|---|---|---|
| Business Acquisition [Line Items] | |||||||||
| Property, plant and equipment | $ 687 | ||||||||
| Goodwill | 48,073 | [1] | |||||||
| Intangible asset | 11,169 | 5,243 | 1,172 | 1,357 | |||||
| Cash and cash equivalents | 1,965 | ||||||||
| Other current assets | 3,713 | ||||||||
| Deferred tax liability | (2,367) | ||||||||
| Other liabilities | (2,521) | ||||||||
| Liability arising from contingent consideration arrangement | (44,028) | ||||||||
| Net assets acquired | 24,463 | ||||||||
| Cash consideration | 24,463 | 17,000 | |||||||
| Contingent consideration | 44,028 | ||||||||
| Amount of total consideration | 68,491 | ||||||||
| Liabilities included in preliminary purchase price allocation | (44,028) | ||||||||
| Net assets acquired | $ 24,463 | ||||||||
|
|||||||||
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Deferred Income Tax Liabilities No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Noncurrent portion of the fair value as of the acquisition date of potential payments under the contingent consideration arrangement, including cash and shares as applicable. No definition available.
|
| X | ||||||||||
|
- Definition
The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash and cash equivalents acquired in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of acquisition cost of a business combination allocated to other liabilities not separately disclosed in the balance sheet. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Oxford Outcomes (Detail) (Oxford Outcomes Limited)
In Thousands, unless otherwise specified |
Jan. 14, 2011
USD ($)
|
Jan. 14, 2011
GBP (£)
|
Jan. 14, 2011
Customer relationships acquired
USD ($)
|
Jan. 14, 2011
Order Backlog
USD ($)
|
|||
|---|---|---|---|---|---|---|---|
| Business Acquisition [Line Items] | |||||||
| Property, plant and equipment | $ 490 | ||||||
| Goodwill | 35,583 | [1] | |||||
| Intangible asset | 6,648 | 618 | |||||
| Cash and cash equivalents | 6,335 | ||||||
| Other current assets | 6,792 | ||||||
| Deferred tax liability | (2,003) | ||||||
| Other liabilities | (2,128) | ||||||
| Liability arising from contingent consideration arrangement | (12,474) | ||||||
| Net assets acquired | 39,861 | ||||||
| Cash consideration | 27,585 | 17,800 | |||||
| Working capital adjustment | 6,383 | ||||||
| Put and call option | 5,893 | ||||||
| Contingent consideration | 12,474 | ||||||
| Amount of total consideration | 52,335 | ||||||
| Liabilities included in preliminary purchase price allocation | (12,474) | ||||||
| Net assets acquired | $ 39,861 | ||||||
|
|||||||
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Deferred Income Tax Liabilities No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition Purchase Price Allocation Working Capital No definition available.
|
| X | ||||||||||
|
- Definition
Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Noncurrent portion of the fair value as of the acquisition date of potential payments under the contingent consideration arrangement, including cash and shares as applicable. No definition available.
|
| X | ||||||||||
|
- Definition
Fair value of noncash consideration given by the acquirer to acquire the entity. Does not include cash paid, the fair value of debt and securities issued and liabilities incurred to acquire the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash and cash equivalents acquired in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of acquisition cost of a business combination allocated to other liabilities not separately disclosed in the balance sheet. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Recognized and Other Non-Recurring items, Net (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Restructuring Cost and Reserve [Line Items] | ||||
| Restructuring charges | $ 4,815 | $ 4,525 | $ 9,817 | |
| Other non-recurring items | 1,111 | |||
| Total | $ 4,815 | $ 5,636 | $ 9,817 | |
| X | ||||||||||
|
- Definition
Expenses charged against earnings in the period of an event that is infrequent in occurrence or unusual in nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The charge against earnings in the period, comprised of costs associated with restructuring activities not otherwise specified in the taxonomy pursuant to a duly authorized plan, excluding a discontinued operation as defined by generally accepted accounting principles. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, but excludes costs associated with the retirement of a long-lived asset and severance costs associated with established compensation plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Restructuring and other non-recurring items - Additional Information (Detail)
|
3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
USD ($)
|
Jun. 30, 2012
USD ($)
|
Sep. 30, 2011
USD ($)
|
Sep. 30, 2012
USD ($)
|
Sep. 30, 2012
EUR (€)
|
Sep. 30, 2011
USD ($)
|
Sep. 30, 2011
Q3 Restructuring Plan
Clinical Research
USD ($)
|
Sep. 30, 2012
Q2 Restructuring Plan
USD ($)
|
Mar. 31, 2011
Q1 Restructuring Plan
USD ($)
|
Sep. 30, 2012
Q1 Restructuring Plan
USD ($)
|
Mar. 31, 2011
Q1 Restructuring Plan
Clinical Research
USD ($)
|
Mar. 31, 2011
Q1 Restructuring Plan
Central Laboratory
USD ($)
|
|
| Restructuring Cost and Reserve [Line Items] | ||||||||||||
| Restructuring charges | $ 4,815,000 | $ 4,525,000 | $ 9,817,000 | $ 4,800,000 | $ 4,600,000 | $ 5,000,000 | $ (100,000) | $ 3,500,000 | $ 1,500,000 | |||
| Resource rationalizations | 1,111,000 | 3,400,000 | ||||||||||
| Lease termination and exit costs | 900,000 | 1,200,000 | 1,000,000 | |||||||||
| Workforce reductions | 3,900,000 | 4,000,000 | ||||||||||
| Agreement settlement charges | 200,000 | 160,000 | ||||||||||
| Discretionary bonus received | 243,000 | 243,000 | 194,000 | |||||||||
| Share-based compensation | $ 620,000 | $ 738,000 | ||||||||||
| X | ||||||||||
|
- Definition
Gain (Loss) On Contract Termination And Business Exit Costs No definition available.
|
| X | ||||||||||
|
- Definition
Restructuring, Settlement and Other Charges No definition available.
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The charge against earnings in the period, comprised of costs associated with restructuring activities not otherwise specified in the taxonomy pursuant to a duly authorized plan, excluding a discontinued operation as defined by generally accepted accounting principles. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, but excludes costs associated with the retirement of a long-lived asset and severance costs associated with established compensation plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination or a discontinued operation as defined by generally accepted accounting principles and costs associated with one-time termination benefits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Details of Movement in Restructuring Provisions Recognized (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
Restructuring - Fiscal 2012 Plan
|
Sep. 30, 2012
Restructuring - Fiscal 2011 Plan
|
Dec. 31, 2011
Restructuring - Fiscal 2011 Plan
|
Dec. 31, 2011
Restructuring - Fiscal 2011 Plan
Q1 Restructuring Plan
|
Dec. 31, 2011
Restructuring - Fiscal 2011 Plan
Q3 Restructuring Plan
|
Sep. 30, 2012
Workforce Reduction
Restructuring - Fiscal 2012 Plan
|
Sep. 30, 2012
Workforce Reduction
Restructuring - Fiscal 2011 Plan
|
Dec. 31, 2011
Workforce Reduction
Restructuring - Fiscal 2011 Plan
|
Dec. 31, 2011
Workforce Reduction
Restructuring - Fiscal 2011 Plan
Q1 Restructuring Plan
|
Dec. 31, 2011
Workforce Reduction
Restructuring - Fiscal 2011 Plan
Q3 Restructuring Plan
|
Sep. 30, 2012
Office Consolidations
Restructuring - Fiscal 2012 Plan
|
Sep. 30, 2012
Office Consolidations
Restructuring - Fiscal 2011 Plan
|
Dec. 31, 2011
Office Consolidations
Restructuring - Fiscal 2011 Plan
|
Dec. 31, 2011
Office Consolidations
Restructuring - Fiscal 2011 Plan
Q1 Restructuring Plan
|
Dec. 31, 2011
Office Consolidations
Restructuring - Fiscal 2011 Plan
Q3 Restructuring Plan
|
|
| Restructuring Cost and Reserve [Line Items] | |||||||||||||||||||
| Provision balance at beginning of period | $ 3,874 | $ 2,234 | $ 1,640 | ||||||||||||||||
| Initial provision recognised | 4,815 | 4,525 | 9,817 | 4,644 | 9,817 | 5,002 | 4,815 | 3,394 | 7,836 | 3,956 | 3,880 | 1,250 | 1,981 | 1,046 | 935 | ||||
| Cash payments | (3,469) | (3,257) | (5,689) | (2,986) | (2,123) | (5,438) | (483) | (1,134) | (251) | ||||||||||
| Amounts released | (150) | (55) | (95) | ||||||||||||||||
| Property, plant and equipment write-off | (263) | (55) | (263) | (55) | |||||||||||||||
| Foreign exchange movement | (4) | 8 | (199) | (4) | (20) | (164) | 28 | (35) | |||||||||||
| Closing provision | $ 1,171 | $ 212 | $ 404 | $ 36 | $ 767 | $ 176 | |||||||||||||
| X | ||||||||||
|
- Definition
Restructuring Charges Related to Asset Write Offs and Closed Facilities No definition available.
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of foreign currency translation adjustment increasing or decreasing the accrual for a specified type of restructuring cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Income Taxes Recognized During Period (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Reconciliation of Provision of Income Taxes [Line Items] | ||||
| Provision for income taxes before restructuring and other non-recurring items | $ 2,889 | $ (202) | $ 9,129 | $ 5,559 |
| Tax impact of restructuring and other non-recurring items | (686) | (705) | (1,230) | |
| Provision for income taxes after restructuring and other non-recurring items | $ 2,889 | $ (888) | $ 8,424 | $ 4,329 |
| X | ||||||||||
|
- Definition
Income Tax Expense (Benefit) Before Nonrecurring Charges No definition available.
|
| X | ||||||||||
|
- Definition
Income Tax Expense (Benefit) For Nonrecurring Charges, Net Of Tax No definition available.
|
| X | ||||||||||
|
- Definition
Income Tax Expense (Benefit) For Nonrecurring Charges, Tax No definition available.
|
| X | ||||||||||
|
- Details
|
|
Income Taxes - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
| Liability for unrecognized tax benefit | $ 5.5 | $ 7.7 |
| Items generating unrecognized tax benefits | 4.6 | 6.5 |
| Interest and related penalties | $ 0.9 | $ 1.2 |
| X | ||||||||||
|
- Definition
Unrecognized Tax Benefits, Current Year Tax Positions No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the total of accruals as of the date of the statement of financial position for interest recognized for an underpayment of income taxes computed by applying the applicable statutory rate of interest to the difference between a tax position recognized for financial reporting purposes and the amount previously taken or expected to be taken in a tax return of the entity and the amount of statutory penalties for a tax position claimed or expected to be claimed by the entity, in its tax return, that does not meet the minimum statutory threshold to avoid payment of penalties. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail)
|
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] | ||||
| Weighted average number of ordinary shares outstanding for basic net income per ordinary share | 59,754,010 | 60,471,985 | 59,939,570 | 60,381,814 |
| Effect of dilutive share options outstanding | 612,127 | 591,035 | 451,629 | 714,650 |
| Weighted average number of ordinary shares for diluted net income per ordinary share | 60,366,137 | 61,063,020 | 60,391,199 | 61,096,464 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share-based Awards - Additional Information (Detail) (USD $)
|
9 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
Employee Stock Plan, 2008 Plan
|
Sep. 30, 2012
Employee Stock Plan, 2008 Plan
Individual Employee
|
Sep. 30, 2012
Employee Stock Plan, 2008 Plan
Minimum
|
Sep. 30, 2012
Employee Stock Plan, 2003 Plan
|
Sep. 30, 2012
Employee Stock Plan, 2003 Plan
Individual Employee
|
Sep. 30, 2012
Stock Option
|
Sep. 30, 2011
Stock Option
|
Sep. 30, 2012
Stock Option
Minimum
|
Sep. 30, 2012
Stock Option
Maximum
|
Sep. 30, 2012
Restricted Stock Units (RSUs)
|
Sep. 30, 2011
Restricted Stock Units (RSUs)
|
Jul. 21, 2008
Restricted Stock Units 2008
|
Sep. 30, 2012
Restricted Stock Units 2008
Minimum
|
Sep. 30, 2012
Restricted Stock Units 2008
Maximum
|
|
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | ||||||||||||||||
| Percentage of option price for fair value of ordinary share | 100.00% | |||||||||||||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | 400,000 | 6,000,000 | 400,000 | 1,000,000 | |||||||||||
| Maximum number of award as percentage of shares outstanding | 10.00% | |||||||||||||||
| Shares vesting period | 5 years | 1 year | 3 years | |||||||||||||
| Shares expiration period | 8 years | |||||||||||||||
| Weighted Average Remaining Contractual Life of Options Outstanding | 4 years 8 months 9 days | 8 years | ||||||||||||||
| Options granted fair value | $ 3.68 | $ 13.93 | ||||||||||||||
| Weighted average fair value per option | $ 8.03 | |||||||||||||||
| Exercisable - number of shares | 2,708,837 | |||||||||||||||
| Exercisable - weighted average remaining contractual life | 3 years 4 months 10 days | |||||||||||||||
| Exercisable - weighted average exercise price | $ 22.41 | |||||||||||||||
| Fully vested total intrinsic value | 11,700,000 | |||||||||||||||
| Intrinsic value of option exercised | 4,800,000 | 1,500,000 | ||||||||||||||
| Fair value of RSU's vested | 0 | 100,000 | ||||||||||||||
| Non-cash stock compensation expense not yet recognized | 21,200,000 | |||||||||||||||
| Unrecognized stock-based compensation expense, weighted average period (years) | 3 years | |||||||||||||||
| Tax benefit on exercise of options | $ 852,000 | $ 500,000 | ||||||||||||||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Percentage of Fair Market Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Expiry Period From Date Of Grant No definition available.
|
| X | ||||||||||
|
- Definition
Share based Compensation Arrangement by Share based Payment Award, Options, Grants in Period, Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Weighted Average Option Price No definition available.
|
| X | ||||||||||
|
- Definition
Tax benefit associated with any equity-based compensation plan other than an employee stock ownership plan (ESOP). The tax benefit results from the deduction by the entity on its tax return for an award of stock that exceeds the cumulative compensation cost for common stock or preferred stock recognized for financial reporting. Includes any resulting tax benefit that exceeds the previously recognized deferred tax asset (excess tax benefits). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
As of the balance sheet date, the aggregate unrecognized cost of equity-based awards made to employees under equity-based compensation awards that have yet to vest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total fair value of equity-based awards for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on options which were exercised (or share units converted) into shares during the reporting period under the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. No definition available.
|
|
Summary of Stock Option Activity (Detail) (Stock Option, USD $)
|
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
|
|
Stock Option
|
|||
| Options Outstanding Number of Shares | |||
| Outstanding at beginning of period | 4,902,818 | ||
| Granted | 829,823 | ||
| Exercised | (410,071) | ||
| Forfeited | (458,006) | ||
| Outstanding at ending of period | 4,864,564 | 4,864,564 | |
| Exercisable at end of period | 2,708,837 | 2,708,837 | |
| Weighted Average Exercise Price | |||
| Outstanding at beginning of period | $ 21.87 | ||
| Granted | $ 21.93 | ||
| Exercised | $ 12.76 | ||
| Forfeited | $ 24.94 | ||
| Outstanding at end of period | $ 22.36 | $ 22.36 | |
| Exercisable at end of period | $ 22.41 | $ 22.41 | |
| Weighted Average Fair Value | |||
| Outstanding at beginning of period | $ 8.61 | ||
| Granted | $ 10.26 | $ 8.53 | $ 9.56 |
| Exercised | $ 5.51 | ||
| Forfeited | $ 9.67 | ||
| Outstanding at end of period | $ 8.94 | $ 8.94 | |
| Exercisable at end of period | $ 8.80 | ||
| Weighted Average Remaining Contractual Life | |||
| Outstanding at end of period | 4 years 8 months 9 days | ||
| Exercisable at end of period | 3 years 4 months 10 days | ||
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Forfeited in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net number of share options (or share units) granted during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares. No definition available.
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. No definition available.
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded. No definition available.
|
| X | ||||||||||
|
- Definition
Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Movement in Non-Vested Share Options (Detail) (Stock Option, USD $)
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
|
Stock Option
|
|
| Number of Shares | |
| Beginning Balance | 2,534,310 |
| Granted | 829,823 |
| Vested | (935,114) |
| Forfeited | (273,292) |
| Ending Balance | 2,155,727 |
| Weighted Average Exercise Price | |
| Beginning Balance | $ 23.30 |
| Granted | $ 21.93 |
| Vested | $ 24.30 |
| Forfeited | $ 23.55 |
| Ending Balance | $ 22.31 |
| Weighted Average Fair Value | |
| Beginning Balance | $ 9.11 |
| Granted | $ 9.56 |
| Vested | $ 9.16 |
| Forfeited | $ 9.06 |
| Ending Balance | $ 9.11 |
| X | ||||||||||
|
- Definition
ShareBased Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeited In Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Forfeited in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Forfeited in Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
ShareBased Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding, Number No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
ShareBased Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options Outstanding, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
|
Schedule of Weighted Average Fair Values and Assumptions Used (Detail) (Stock Option, USD $)
|
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
|
|
Stock Option
|
|||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Weighted average fair value | $ 10.26 | $ 8.53 | $ 9.56 |
| Assumptions: | |||
| Expected volatility | 50.00% | 45.00% | |
| Dividend yield | 0.00% | 0.00% | |
| Risk-free interest rate | 0.69% | ||
| Risk-free interest rate, minimum | 1.50% | ||
| Risk-free interest rate, maximum | 2.30% | ||
| Expected life | 5 years | 5 years | |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares. No definition available.
|
| X | ||||||||||
|
- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of RSU Activity (Detail) (Restricted Stock Units (RSUs), USD $)
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
|
Restricted Stock Units (RSUs)
|
|
| Options Outstanding Number of Shares | |
| Outstanding at beginning of period | 365,000 |
| Granted | 244,000 |
| Ordinary shares issued | |
| Forfeited | (150,000) |
| Outstanding at ending of period | 459,000 |
| Weighted Average Fair Value | |
| Outstanding at beginning of period | $ 19.46 |
| Granted | $ 20.87 |
| Ordinary shares issued | |
| Forfeited | $ 20.89 |
| Outstanding at end of period | $ 19.74 |
| Weighted Average Remaining Contractual Life | |
| Outstanding at end of period | 2 years 1 month 21 days |
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Cancelled and Forfeited in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Exercises in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Unvested, Number No definition available.
|
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Unvested, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Non-Cash Stock Compensation Expense (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 2,981 | $ 2,218 | $ 8,834 | $ 6,355 |
|
Direct costs
|
||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | 1,643 | 1,222 | 4,526 | 3,502 |
|
Selling, General and Administrative Expense
|
||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | 1,338 | 996 | 3,688 | 2,853 |
|
Restructuring and other non-recurring items
|
||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 620 | |||
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Share Capital - Additional Information (Detail) (USD $)
In Millions, except Share data, unless otherwise specified |
9 Months Ended | 10 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2012
|
Oct. 27, 2011
Maximum
|
Nov. 22, 2011
Plan 1
|
Nov. 22, 2011
Plan 2
|
Feb. 21, 2012
Plan 3
|
Apr. 27, 2012
Plan 4
|
Apr. 27, 2012
Plan 4
Maximum
|
Jul. 30, 2012
Plan 5
|
Jul. 30, 2012
Plan 5
Maximum
|
|
| Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] | ||||||||||
| Share repurchase program value | $ 50 | $ 10 | $ 10 | $ 20 | $ 20 | $ 10 | ||||
| Share repurchase plans, start date | Nov. 23, 2011 | Jan. 01, 2012 | Feb. 22, 2012 | Apr. 27, 2012 | Jul. 30, 2012 | |||||
| Share repurchase plans, end date | Dec. 31, 2011 | Feb. 20, 2012 | Apr. 22, 2012 | Jul. 18, 2012 | Oct. 26, 2012 | |||||
| Ordinary shares repurchased | 738,341 | 1,283,938 | ||||||||
| Ordinary shares repurchased, value | $ 15.6 | $ 24.6 | ||||||||
| X | ||||||||||
|
- Definition
Share Repurchase Program, Repurchase Period End Date No definition available.
|
| X | ||||||||||
|
- Definition
Share Repurchase Program, Repurchase Period Start Date No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of shares that have been repurchased and retired during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount authorized by an entity's Board of Directors under a stock repurchase plan. No definition available.
|
|
Distribution of Net Revenue by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | $ 285,502 | $ 240,772 | $ 814,842 | $ 703,114 |
|
Ireland
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 41,129 | 13,872 | 110,891 | 67,305 |
|
Rest Of Europe
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 80,466 | 91,696 | 253,740 | 258,641 |
|
U.S.
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 129,564 | 103,992 | 351,548 | 290,382 |
|
Rest of World
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | $ 34,343 | $ 31,212 | $ 98,663 | $ 86,786 |
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Net Revenue by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | $ 285,502 | $ 240,772 | $ 814,842 | $ 703,114 |
|
Clinical Research
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 261,524 | 221,226 | 750,381 | 650,233 |
|
Central Laboratory
|
||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | $ 23,978 | $ 19,546 | $ 64,461 | $ 52,881 |
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Operating Income Loss Before Restructuring Charges No definition available.
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Operating Income Loss Before Restructuring Charges No definition available.
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 165,081 | $ 168,461 |
|
Ireland
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 107,960 | 109,953 |
|
Rest Of Europe
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 15,344 | 16,419 |
|
U.S.
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 32,445 | 33,086 |
|
Rest of World
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 9,332 | $ 9,003 |
| X | ||||||||||
|
- Definition
Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Property, Plant and Equipment, Net, by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 165,081 | $ 168,461 |
|
Clinical Research
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 147,986 | 150,169 |
|
Central Laboratory
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 17,095 | $ 18,292 |
| X | ||||||||||
|
- Definition
Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Depreciation and Amortization by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | $ 10,601 | $ 9,667 | $ 32,233 | $ 27,969 |
|
Ireland
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | 4,380 | 3,628 | 13,381 | 9,810 |
|
Rest Of Europe
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | 1,691 | 2,121 | 5,430 | 5,557 |
|
U.S.
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | 3,631 | 2,995 | 10,568 | 9,463 |
|
Rest of World
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | $ 899 | $ 923 | $ 2,854 | $ 3,139 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Distribution of Depreciation and Amortization by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | $ 10,601 | $ 9,667 | $ 32,233 | $ 27,969 |
|
Clinical Research
|
||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | 9,604 | 8,496 | 29,506 | 24,193 |
|
Central Laboratory
|
||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | $ 997 | $ 1,171 | $ 2,727 | $ 3,776 |
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Total Assets by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Assets | $ 1,135,229 | $ 1,035,467 |
|
Ireland
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 433,171 | 414,510 |
|
Rest Of Europe
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 237,288 | 216,313 |
|
U.S.
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 415,761 | 363,527 |
|
Rest of World
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | $ 49,009 | $ 41,117 |
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Total Assets by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Assets | $ 1,135,229 | $ 1,035,467 |
|
Clinical Research
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 1,073,526 | 980,283 |
|
Central Laboratory
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | $ 61,703 | $ 55,184 |
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|